Often deadly "triple-negative" breast cancers might be effectively treated in many cases with a drug that targets a previously unknown vulnerability in the tumors, according to a UC San Francisco researcher who described her discovery in a study published online October 3, 2013 in the journal Cancer Cell.
UCSF researcher Luika Timmerman, PhD, an investigator in the UCSF Helen Diller Family Comprehensive Cancer Center, found that many cell lines obtained from triple-negative breast cancer are especially dependent on cystine, one of the 20 amino acids that are the building blocks of proteins that all cells need. Timmerman used an FDA-approved drug to inhibit activity of a transporter protein that ferries cystine into triple-negative breast cancer cells, and found that it significantly inhibited their growth in culture and when the cancer cells were transplanted into mice.
Roughly one in six women with breast cancer have triple-negative breast cancer, and only about three out of four with this type survive five years or more. These tumors sometimes grow aggressively, advancing from being undetectable to becoming difficult-to-treat between regular screening mammography exams, for instance.
Drugs now are available that effectively target the estrogen and HER2 receptor proteins, which are found in many breast tumors, and these drugs spare most normal cells in the body. However, triple-negative breast cancers are difficult to treat effectively because they do not make either of these receptors. To treat patients with triple-negative breast cancer, physicians instead use older chemotherapies that produce side effects in normal tissues, thus limiting the doses that patients can receive.
Timmerman found that she could significantly slow growth of triple-negative tumors using an FDA-approved anti-inflammatory drug called sulfasalazine to block a specific cystine transporter called xCT. While sulfasalazine itself would not be appropriate for treating cancer, Timmerman said, it could serve as a "lead compound" that could be used to develop drugs that specifically target xCT on tumor cells.
"This study of human tumors in mice and of breast cancer cell lines demonstrates the potential of targeting not only this cystine transporter, but also other metabolic abnormalities in cancer," Timmerman said.
Timmerman has spent several years studying the abnormal metabolic behavior of cancer cells, which can differ substantially from the metabolism of normal cells. "Different cancers seem to acquire different metabolic abnormalities that might in some cases give them a growth or survival advantage," she said.
"One of the strengths of this study was the large number of different cell lines I was able to test. When I saw similar results in many samples, I felt I was looking at a fundamental metabolic behavior that we could exploit to specifically target triple-negative tumors that overexpress the xCT cystine transporter, a significant group of previously untargettable tumors."
Timmerman initially focused on investigating the metabolism of the amino acid glutamine among different breast cancer-derived cell lines because glutamine metabolism was long known to be perturbed in cancer. She matched genetic "microarray" data that tracks gene activity to functional differences among tumors and tumor cell lines in culture.
But she also measured amino acids and other molecules in cell culture to detect metabolic changes. When she did so, she noticed that cystine and glutamate levels are frequently correlated in triple-negative cancers. A series of experiments led to the discovery that the cystine transporter xCT was abundant and active on many triple-negative tumors and tumor cell lines. Timmerman then tested sulfasalazine on tumors grown in mice and in tumor cell lines and found that blocking xCT activity strongly retarded the growth of triple-negative tumors.
"We have identified a compelling therapeutic target commonly expressed by breast tumors of poorest prognosis, and a lead compound for rapid, effective drug development," Timmerman said.
Explore further: Aggressive breast cancers may be sensitive to drugs clogging their waste disposal
Medical Xpress on facebook
Related Stories
Aggressive breast cancers may be sensitive to drugs clogging their waste disposal
Aug 12, 2013
In a new paper in Cancer Cell, a team led by Judy Lieberman, PhD, of Boston Children's Hospital's Program in Cellular and Molecular Medicine reports "triple-negative" breast cancers may be vulnerable to drugs that attack ...
Breaking the backbone of triple-negative breast cancers
Mar 19, 2012
Putting the brakes on an abundant growth-promoting protein causes breast tumors to regress, according to a study published on March 19th in the Journal of Experimental Medicine.
Paragazole excels in preclinical models of triple-negative breast cancer
Apr 08, 2013
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative ...
Drug shows promise for triple-negative breast cancer
Jul 03, 2012
(Medical Xpress) -- A promising new therapy for hard-to-treat triple-negative breast cancer has been reported in the journal Breast Cancer Research by a team at the Tulane University School of Medicine, led by ...
Successful treatment of triple negative breast cancer by modulation of the OGF-OGFr axis
Aug 09, 2013
Researchers at The Pennsylvania State University College of Medicine, led by Dr. Ian S. Zagon, have discovered that a novel biological pathway, the OGF-OGFr axis, can be modulated in human triple-negative breast cancer cells ...
Recommended for you
Can eating watercress help fight breast cancer?
3 hours ago
The University of Reading is playing a leading role in a new study which will examine the effects of eating watercress on breast cancer patients.
'Critical gaps' in breast cancer research
5 hours ago
Critical gaps in breast cancer research could see the loss of around 185,000* lives by 2030 if they are not urgently addressed, according to a major new study co-authored by researchers from King's College ...
New pain-free treatment for prostate cancer? Not quite
5 hours ago
If you or someone close to you has lived with prostate cancer, you've probably come across dozens of emerging treatments in your hours of Googling. One such treatment, focal therapy, has been dubbed the "new ...
Scientists identify potential new drug for inherited cancer
6 hours ago
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a new drug candidate for an inherited form of cancer with no known cure.
International study shows efficacy of new gastric cancer drug
17 hours ago
This international trial, published in The Lancet, is one of the largest phase III trials in second-line treatment of gastric cancer. Standard care for advanced gastric cancer, known as first-line treatment, is based on che ...
Skin cancer patients not avoiding sun, study suggests
18 hours ago
(HealthDay)—Some people with melanoma aren't cautious about sun exposure, a small new study suggests, even though ultraviolet (UV) radiation from the sun is a major cause of skin cancer.
User comments
© Medical Xpress 2011-2013, Phys.org network
Often deadly "triple-negative" breast cancers might be effectively treated in many cases with a drug that targets a previously unknown vulnerability in the tumors, according to a UC San Francisco researcher who described her discovery in a study published online October 3, 2013 in the journal Cancer Cell.
UCSF researcher Luika Timmerman, PhD, an investigator in the UCSF Helen Diller Family Comprehensive Cancer Center, found that many cell lines obtained from triple-negative breast cancer are especially dependent on cystine, one of the 20 amino acids that are the building blocks of proteins that all cells need. Timmerman used an FDA-approved drug to inhibit activity of a transporter protein that ferries cystine into triple-negative breast cancer cells, and found that it significantly inhibited their growth in culture and when the cancer cells were transplanted into mice.
Roughly one in six women with breast cancer have triple-negative breast cancer, and only about three out of four with this type survive five years or more. These tumors sometimes grow aggressively, advancing from being undetectable to becoming difficult-to-treat between regular screening mammography exams, for instance.
Drugs now are available that effectively target the estrogen and HER2 receptor proteins, which are found in many breast tumors, and these drugs spare most normal cells in the body. However, triple-negative breast cancers are difficult to treat effectively because they do not make either of these receptors. To treat patients with triple-negative breast cancer, physicians instead use older chemotherapies that produce side effects in normal tissues, thus limiting the doses that patients can receive.
Timmerman found that she could significantly slow growth of triple-negative tumors using an FDA-approved anti-inflammatory drug called sulfasalazine to block a specific cystine transporter called xCT. While sulfasalazine itself would not be appropriate for treating cancer, Timmerman said, it could serve as a "lead compound" that could be used to develop drugs that specifically target xCT on tumor cells.
"This study of human tumors in mice and of breast cancer cell lines demonstrates the potential of targeting not only this cystine transporter, but also other metabolic abnormalities in cancer," Timmerman said.
Timmerman has spent several years studying the abnormal metabolic behavior of cancer cells, which can differ substantially from the metabolism of normal cells. "Different cancers seem to acquire different metabolic abnormalities that might in some cases give them a growth or survival advantage," she said.
"One of the strengths of this study was the large number of different cell lines I was able to test. When I saw similar results in many samples, I felt I was looking at a fundamental metabolic behavior that we could exploit to specifically target triple-negative tumors that overexpress the xCT cystine transporter, a significant group of previously untargettable tumors."
Timmerman initially focused on investigating the metabolism of the amino acid glutamine among different breast cancer-derived cell lines because glutamine metabolism was long known to be perturbed in cancer. She matched genetic "microarray" data that tracks gene activity to functional differences among tumors and tumor cell lines in culture.
But she also measured amino acids and other molecules in cell culture to detect metabolic changes. When she did so, she noticed that cystine and glutamate levels are frequently correlated in triple-negative cancers. A series of experiments led to the discovery that the cystine transporter xCT was abundant and active on many triple-negative tumors and tumor cell lines. Timmerman then tested sulfasalazine on tumors grown in mice and in tumor cell lines and found that blocking xCT activity strongly retarded the growth of triple-negative tumors.
"We have identified a compelling therapeutic target commonly expressed by breast tumors of poorest prognosis, and a lead compound for rapid, effective drug development," Timmerman said.
Explore further: Aggressive breast cancers may be sensitive to drugs clogging their waste disposal
Medical Xpress on facebook
Related Stories
Aggressive breast cancers may be sensitive to drugs clogging their waste disposal
Aug 12, 2013
In a new paper in Cancer Cell, a team led by Judy Lieberman, PhD, of Boston Children's Hospital's Program in Cellular and Molecular Medicine reports "triple-negative" breast cancers may be vulnerable to drugs that attack ...
Breaking the backbone of triple-negative breast cancers
Mar 19, 2012
Putting the brakes on an abundant growth-promoting protein causes breast tumors to regress, according to a study published on March 19th in the Journal of Experimental Medicine.
Paragazole excels in preclinical models of triple-negative breast cancer
Apr 08, 2013
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative ...
Drug shows promise for triple-negative breast cancer
Jul 03, 2012
(Medical Xpress) -- A promising new therapy for hard-to-treat triple-negative breast cancer has been reported in the journal Breast Cancer Research by a team at the Tulane University School of Medicine, led by ...
Successful treatment of triple negative breast cancer by modulation of the OGF-OGFr axis
Aug 09, 2013
Researchers at The Pennsylvania State University College of Medicine, led by Dr. Ian S. Zagon, have discovered that a novel biological pathway, the OGF-OGFr axis, can be modulated in human triple-negative breast cancer cells ...
Recommended for you
Can eating watercress help fight breast cancer?
3 hours ago
The University of Reading is playing a leading role in a new study which will examine the effects of eating watercress on breast cancer patients.
'Critical gaps' in breast cancer research
5 hours ago
Critical gaps in breast cancer research could see the loss of around 185,000* lives by 2030 if they are not urgently addressed, according to a major new study co-authored by researchers from King's College ...
New pain-free treatment for prostate cancer? Not quite
5 hours ago
If you or someone close to you has lived with prostate cancer, you've probably come across dozens of emerging treatments in your hours of Googling. One such treatment, focal therapy, has been dubbed the "new ...
Scientists identify potential new drug for inherited cancer
6 hours ago
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a new drug candidate for an inherited form of cancer with no known cure.
International study shows efficacy of new gastric cancer drug
17 hours ago
This international trial, published in The Lancet, is one of the largest phase III trials in second-line treatment of gastric cancer. Standard care for advanced gastric cancer, known as first-line treatment, is based on che ...
Skin cancer patients not avoiding sun, study suggests
18 hours ago
(HealthDay)—Some people with melanoma aren't cautious about sun exposure, a small new study suggests, even though ultraviolet (UV) radiation from the sun is a major cause of skin cancer.
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment